Table 3.
The effect of PAI-1 -675 4G/5G polymorphism on CAD risk
| Comparison | Study | No. ofstudies | Test of association | Heterogeneity | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| OR (95% CI) | Z | P Value | χ 2 | P Value | I 2 (%) | |||
| 4G/4G + 4G/5G vs. 5G/5G | Overall | 72 | 1.19 (1.10-1.28) | 4.54 | < 0.00001 | 144.13 | < 0.00001 | 51 |
| 4G/4G + 4G/5G vs. 5G/5G | Adjusted | 10 | 1.20 (1.03-1.40) | 2.29 | 0.02 | 13.95 | 0.12 | 36 |
| 4G/4G + 4G/5G vs. 5G/5G | Caucasian | 45 | 1.10 (1.02-1.19) | 2.54 | 0.01 | 70.61 | 0.007 | 38 |
| 4G/4G + 4G/5G vs. 5G/5G | Asian | 24 | 1.46 (1.21-1.75) | 4.03 | < 0.0001 | 55.19 | 0.0002 | 58 |
| 4G/4G + 4G/5G vs. 5G/5G | African | 2 | 1.38 (0.70-2.70) | 0.93 | 0.35 | 5.12 | 0.02 | 80 |
| 4G/4G + 4G/5G vs. 5G/5G | MI | 39 | 1.15 (1.06-1.25) | 3.27 | 0.001 | 68.35 | 0.002 | 44 |
| 4G/4G + 4G/5G vs. 5G/5G | Early-onset | 12 | 1.21 (1.02-1.43) | 2.20 | 0.03 | 6.31 | 0.71 | 0 |
| 4G/4G + 4G/5G vs. 5G/5G | Late-onset | 4 | 0.90 (0.72-1.13) | 0.89 | 0.37 | 1.83 | 0.61 | 0 |
| 4G/4G + 4G/5G vs. 5G/5G | Male | 13 | 1.10 (1.01-1.20) | 2.10 | 0.04 | 7.23 | 0.84 | 0 |
| 4G/4G + 4G/5G vs. 5G/5G | Female | 4 | 1.03 (0.89-1.19) | 0.34 | 0.73 | 4.54 | 0.21 | 34 |
| 4G/4G + 4G/5G vs. 5G/5G | T2DM | 4 | 2.23 (1.27-3.92) | 2.80 | 0.005 | 0.48 | 0.79 | 0 |
| 4G/4G + 4G/5G vs. 5G/5G | Non-T2DM | 3 | 1.64 (1.19-2.25) | 3.03 | 0.002 | 0.57 | 0.75 | 0 |
MI, myocardium infarction; T2DM, type 2 diabetes.